ArticleTranslational oncology2026
GPR107-EGFR crosstalk promotes ovarian cancer metastasis by regulating IL-6 release via PI3K/AKT/NF-κB signaling pathway.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OVCA) has the highest mortality rate among all gynecological malignancies. Epidermal growth factor receptor (EGFR) is commonly overexpressed in epithelial OVCA (30-98%) and is significantly positively correlated with poor patient prognosis. However, therapeutic drugs targeting EGFR have not shown promising results, indicating the existence of other potential mechanisms. G-protein-coupled receptor (GPCR) families were reported to crosstalk with EGFR, jointly affecting the activation of downstream signaling pathway networks. G protein-coupled receptor 107 (GPR107), a novel orphan GPCR, is overexpressed in tumors and is involved in cancer progression. Little is known about the role of GPR107 in OVCA progression. In this study, the underlying mechanism of GPR107-EGFR crosstalk and its critical function in OVCA progression were investigated. GPR107, which was highly expressed in OVCA and was associated with advanced clinical stages, could interact with EGFR on the cell membrane and promoted the invasion, migration, and epithelial mesenchymal transition (EMT) of OVCA. Mechanistically, GPR107-EGFR crosstalk promoted EGFR phosphorylation and downstream PI3K/AKT/NF-κB activation, resulting in autocrine IL-6 secretion, which facilitated OVCA metastasis both in vitro and in vivo. Monoclonal antibodies targeting IL-6 could inhibit OVCA metastasis induced by GPR107. In conclusion, our study highlights the importance of GPR107-EGFR crosstalk in OVCA metastasis by clarifying the function and molecular mechanism of GPR107-EGFR crosstalk, and provides a novel direction for developing new treatment strategies for OVCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.